February 8, 2017

Quarterly Financial Summary
(For the first nine months of the fiscal year ending March 31, 2017)
[Under Japanese GAAP]
(Consolidated)

Listed Company: Zeria Pharmaceutical Co., Ltd. (Stock Exchange: First Section of Tokyo Stock Exchange)
Code Number: 4559 (URL: http://www.zeria.co.jp/)
Representative: Mitsuhiro Ibe, Representative Director, President & COO
Person in charge of reference: Shinya Sugawara, Director, Public Relations Division TEL (03) 3661-1039
Scheduled date to submit the Quarterly Securities Report: February 10, 2017
Scheduled date to commencement of dividend payments: –
Preparation of supplementary documents to the quarterly financial results: None
Holding of quarterly financial results presentation: None

(Amounts under a million yen are truncated.)

1. Consolidated Financial Highlights (April 1, 2016 through December 31, 2016)

(1) Consolidated Financial Results (cumulative)

(Percentage figures indicate changes from the same period of the previous year.)

	Net sales		Operating income		Ordinary income		Profit attributable to owners of parent	
Nine months ended	Million yen	%	Million yen	%	Million yen	%	Million yen	%
December 31, 2016	49,043	4.2	3,641	(4.0)	3,502	(7.0)	2,873	(13.8)
December 31, 2015	47,054	2.8	3,792	13.5	3,766	13.0	3,335	5.5

Note: Comprehensive income: For the nine months ended December 31, 2016: (3,090) million yen [–%]
For the nine months ended December 31, 2015: 3,347 million yen [24.9%]

	Basic earnings per share	Diluted earnings per share
Nine months ended	Yen	Yen
December 31, 2016	54.10	–
December 31, 2015	62.79	–

(2) Consolidated Financial Position

	Total assets	Net assets	Equity ratio	Net assets per share
As of	Million yen	Million yen	%	Yen
December 31, 2016	112,805	58,727	51.9	1,103.23
March 31, 2016	119,178	64,067	53.5	1,199.94

Reference: Equity: As of December 31, 2016: 58,598 million yen March 31, 2016: 63,734 million yen

2. Dividends

	Annual dividends				
	First quarter	Second quarter	Third quarter	Year-end	Total
	Yen	Yen	Yen	Yen	Yen
Year ended March 31, 2016	–	15.00	–	16.00	31.00
Year ending March 31, 2017	–	16.00	–		
Year ending March 31, 2017 (Forecast)				16.00	32.00

Note: Revision of the forecast of dividends most recently announced: None

3. Consolidated Financial Forecast for the Fiscal Year Ending March 31, 2017 (April 1, 2016 through March 31, 2017)

(Percentage figures indicate changes from the same period of the previous year.)

	Net sales		Operating income		Ordinary income		Profit attributable to owners of parent		Basic earnings per share
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Yen
Full year	66,000	5.6	4,800	5.1	4,600	3.4	3,600	2.5	67.78

Note: Revision of the financial forecast most recently announced: None

* Notes

(1) Significant changes of subsidiaries during the nine months ended December 31, 2016 (changes in specified subsidiaries resulting in changes in scope of consolidation): None

Inclusion: – (Company name: –) Exclusion: – (Company name: –)

(2) Application of special accounting for preparing the quarterly consolidated financial statements: Yes

(3) Changes in the accounting policies, changes in accounting estimates, and restatement of prior period financial statements after error corrections

1) Changes in accounting policies due to revisions to accounting standards and other regulations: Yes
2) Changes in accounting policies due to other reasons: None
3) Changes in accounting estimates: None
4) Restatement of prior period financial statements after error corrections: None

(4) Number of shares issued (common stock)

1) Number of shares issued as of the end of the period (including treasury stock):
As of December 31, 2016: 53,119,190 shares As of March 31, 2016: 53,119,190 shares
2) Number of shares of treasury stock as of the end of the period:
As of December 31, 2016: 4,189 shares As of March 31, 2016: 3,871 shares
3) Average number of shares during the period (cumulative from the beginning of the fiscal year):
For the nine months ended December 31, 2016: 53,115,221 shares
For the nine months ended December 31, 2015: 53,115,709 shares

* Indication about Carrying-Out of the Quarterly Review Procedures

This Quarterly Financial Summary is not subject to the quarterly review procedures based on the Financial Instruments and Exchange Act of Japan. At the time of disclosure of this Quarterly Financial Summary, the quarterly review procedures for quarterly consolidated financial statements based on the Financial Instruments and Exchange Act have not been completed.

* Cautionary Statement of Appropriate Use of Financial Forecast and Other Special Matters

The description about the future including the projection in this document is based on information available to the Company at present and certain presumptions which the Company considers reasonable. Consequently, any descriptions herein do not constitute assurances regarding actual results by the Company. The actual results for future terms may differ from the information in this document due to various factors.